Insomnia does more than ruin a night’s rest, it may actively worsen sepsis-induced acute lung injury through a specific immune pathway. Researchers have identified the protein tyrosine phosphatase PTPN6 as a critical molecular bridge connecting poor sleep to pulmonary inflammation in sepsis.
The study, published in Frontiers in Immunology, integrated Mendelian randomization, transcriptomics, single-cell RNA sequencing, and machine learning to trace how insomnia aggravates sepsis-associated lung injury, and pinpointed PTPN6 as the most promising therapeutic target in the chain.
What they found
The analysis proceeded through several layers:
- Mendelian randomization first established a causal relationship: insomnia increases susceptibility to sepsis at the genetic level.
- Weighted gene co-expression network analysis identified 1,294 genes that are dysregulated in both insomnia and sepsis-induced acute lung injury (SALI).
- Machine learning models, random forest, support vector machine, and k-nearest neighbors, narrowed the field to three hub genes: ISG20, MYO1F, and PTPN6. Of these, PTPN6 emerged as the strongest candidate after further diagnostic and prognostic evaluation.
- In vivo validation: Sleep-deprived mice exposed to lipopolysaccharide (LPS) developed worse lung injury, with elevated levels of the inflammatory cytokines IL-1beta, IL-6, and TNF-alpha.
- In vitro validation: Overexpressing PTPN6 in macrophages suppressed pro-inflammatory cytokine production, reduced STAT3 phosphorylation, and decreased M1 macrophage polarization, a key driver of inflammatory damage.
The mechanism appears to run through the JAK/STAT3 signaling pathway: PTPN6 acts as a brake on this inflammatory cascade, and when its expression is inadequate, as the data suggest happens in insomnia, the brake fails, amplifying the lung’s inflammatory response to sepsis.
Why it matters
Sepsis remains one of the deadliest conditions in intensive care, and acute lung injury is its most common fatal complication. The finding that insomnia causally worsens this pathway, and that PTPN6 sits at the junction, opens two practical avenues. First, it provides a molecular rationale for prioritizing sleep in sepsis prevention and critical care management. Second, PTPN6 itself may be a druggable target: compounds that boost its expression or activity could dampen the runaway inflammation that drives lung injury in septic patients with comorbid sleep disruption.
Limits
The Mendelian randomization and transcriptional analyses are computational, not clinical. The in vivo data come from mouse models, and the in vitro work from macrophage cell lines. The authors note that “further mechanistic investigations and comprehensive clinical validation are required” before any therapeutic application. Human data linking insomnia severity to PTPN6 levels in septic patients remain to be collected.
Bottom line
Insomnia is not merely a risk factor for worse sepsis outcomes, the data suggest it is causally embedded in the inflammatory machinery. PTPN6, identified through machine learning across multiple omics layers, is the most promising candidate for intervening in that connection. Confirmation in clinical cohorts will determine whether this biomarker becomes actionable.
Source
Zhang J, et al. A machine learning integrated multi-omics framework for risk prediction and target discovery in insomnia aggravated sepsis induced acute lung injury. Front Immunol. 2026 Jun 1;17:1721749. DOI: 10.3389/fimmu.2026.1721749. PMID: 42305536.